<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860807</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA035054-01</org_study_id>
    <secondary_id>R01DA035054</secondary_id>
    <nct_id>NCT01860807</nct_id>
  </id_info>
  <brief_title>Trial of Ibudilast for Methamphetamine Dependence</brief_title>
  <acronym>IBUD ph II</acronym>
  <official_title>Randomized Trial of Ibudilast for Methamphetamine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to test the safety and potential efficacy of ibudilast to
      treat methamphetamine dependence. The study hypotheses are that ibudilast will reduce
      methamphetamine use and increase treatment retention more than placebo among patients seeking
      treatment for methamphetamine dependence. As HIV infection is a common complication of
      methamphetamine dependence, half of the participants will be HIV positive and the study will
      assess whether ibudilast also improves HIV related outcomes (e.g. medication adherence, CD4
      count, risk behaviors).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ibudilast (IBUD) is a macrophage migration inhibitory factor (MIF) and phosphodiesterase
      (PDE)-4 and -10 inhibitor at peak clinical exposures (Rolan, Hutchinson et al. 2009) that
      increases glial cell line-derived neurotrophic factor (GDNF) expression (Mizuno, Kurotani et
      al. 2004) and reduces microglial activation (Suzumura, Ito et al. 1999; Suzumura, Ito et al.
      2003), including HIV-induced glial activation (Kiebala and Maggirwar 2011). IBUD
      significantly reduces methamphetamine (MA) prime- and stress-induced reinstatement of MA
      seeking in rats (Beardsley, Shelton et al. 2010) and has multiple effects that may make it an
      effective treatment for MA dependence including amelioration of dopaminergic and
      neuroinflammatory dysfunction. Multiple studies implicate glial cells in a variety of
      neurodegenerative diseases (Hirsch and Hunot 2009; Sidoryk-Wegrzynowicz, Wegrzynowicz et al.
      2011) including MA dependence and HIV infection (Nath 2010). Activated glial cells secrete
      pro-inflammatory mediators (Minghetti, Ajmone-Cat et al. 2005) that may exacerbate MA-induced
      dopaminergic dysfunction. Glial cells also produce neurotrophic factors, including GDNF,
      which may ameliorate dopaminergic dysfunction (Pascual, Hidalgo-Figueroa et al. 2008). Thus,
      IBUD may be an effective medication for MA dependence due to its modulation of glial cell
      activation resulting in amelioration of dopaminergic and neurocognitive dysfunction and
      improved treatment outcomes in MA dependence. IBUD may also have unique effects in HIV
      positive MA users as it may additionally block the degradation of neuronal integrity seen in
      HIV infection (Chana, Everall et al. 2006; Dash, Gorantla et al. 2011).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methamphetamine Use</measure>
    <time_frame>12 weeks</time_frame>
    <description>End of treatment methamphetamine abstinence</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Methamphetamine Dependence</condition>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Ibudilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibudilast 50 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibudilast</intervention_name>
    <arm_group_label>Ibudilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older;

          2. meet DSM-IV-TR criteria for MA dependence (SCID verified);

          3. a MA-positive urine drug screen at one or more visit during the two week lead-in
             period;

          4. seeking treatment for MA problems;

          5. willing and able to comply with study procedures;

          6. provide written informed consent;

          7. English speaking

          8. reside within 35 miles of the clinical research site; and

          9. if female of childbearing potential, not pregnant or lactating and willing to use a
             medically reliable method of birth control during the trial (e.g., birth control
             pills, Depo-Provera, and/or condoms with spermicide).

        Exclusion Criteria:

          1. a medical condition that, in the study physician's judgment, may interfere with safe
             study participation (e.g., active TB; unstable cardiac, renal, or liver disease;
             uncontrolled hypertension; unstable diabetes);

          2. CD4 count &lt; 50 cells/mm3 (suggestive of advanced HIV infection)

          3. AST, ALT, or GGT &gt; 3 times upper normal limit;

          4. A corrected QT of &gt; 450 msecs in men or &gt; 460 msec in women on at least two ECGs
             during the baseline period, or clinical risk factors for Torsades de Pointes (e.g.
             (e.g., heart failure, hypokalemia, family history of Long QT Syndrome), or requiring
             ongoing treatment with concomitant medication(s) with established risk of Torsades de
             Pointes (e.g. Amiodarone, Arsenic trioxide, Astemizole, Bepridil, Chloroquine,
             Chlorpromazine, Cisapride, Citalopram, Clarithromycin, Disopyramide, Dofetilide,
             Domperidone, Droperidol, Erythromycin, Flecainide, Halofantrine, Haloperidol,
             Ibutilide, Levomethadyl, Mesoridazine, Methadone, Moxifloxacin, Pentamidine, Pimozide,
             Probucol, Procainamide, Quinidine, Sotalol, Sparfloxacin, Terfenadine, Thioridazine,
             Vandetanib);

          5. current ongoing treatment with psychotropic medications (e.g., antidepressants,
             antipsychotics, antiepileptics, sedative/hypnotics, narcotic analgesics);

          6. a neurological disorder (e.g., organic brain disease, dementia) or a medical condition
             which would make study agent compliance difficult or which would compromise informed
             consent;

          7. a major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar
             disorder) as assessed by the SCID;

          8. attempted suicide in the past 3 years and/or serious suicidal intention or plan in the
             past year as assessed by the C-SSRS;

          9. currently on prescription medication that is contraindicated for use with IBUD
             including alpha or beta agonists, theophylline, or other sympathomimetics;

         10. current dependence on cocaine, opiates, alcohol, or benzodiazepines as defined by
             DSM-IV-TR;

         11. alcohol dependence within the past year;

         12. greater than one urine specimens during the lead-in with a riboflavin concentration of
             &lt; 900 ng/ml as assessed via UV fluorescence;

         13. a history of sensitivity to IBUD; or

         14. any other circumstances that, in the opinion of the investigators, would compromise
             participant safety;

         15. current participation in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Heinzerling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Vine Street Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <results_first_submitted>January 6, 2019</results_first_submitted>
  <results_first_submitted_qc>January 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2019</results_first_posted>
  <last_update_submitted>January 6, 2019</last_update_submitted>
  <last_update_submitted_qc>January 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Keith Heinzerling</investigator_full_name>
    <investigator_title>Associate Professor in Residence</investigator_title>
  </responsible_party>
  <keyword>methamphetamine</keyword>
  <keyword>ibudilast</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibudilast</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT01860807/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ibudilast</title>
          <description>Ibudilast 50 mg twice daily
Ibudilast</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matching placebo twice daily
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibudilast</title>
          <description>Ibudilast 50 mg twice daily
Ibudilast</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>matching placebo twice daily
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="125"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.9" spread="9.0"/>
                    <measurement group_id="B2" value="42.8" spread="10.5"/>
                    <measurement group_id="B3" value="41.9" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline methamphetamine use on 26 or more days per month</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Methamphetamine Use</title>
        <description>End of treatment methamphetamine abstinence</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibudilast</title>
            <description>Ibudilast 50 mg twice daily
Ibudilast</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo twice daily
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Methamphetamine Use</title>
          <description>End of treatment methamphetamine abstinence</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 week medication treatment period and 4 week post-treatment follow-up period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ibudilast</title>
          <description>Ibudilast 50 mg twice daily
Ibudilast</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>matching placebo twice daily
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study did not determine if ibudilast may help patients who have stopped methamphetamine use prior to starting medication</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Keith Heinzerling MD</name_or_title>
      <organization>UCLA</organization>
      <phone>310-319-4700</phone>
      <email>kheinzerling@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

